Bayer

This study tested if a higher dose of an existing eye injection (aflibercept 8 mg) could be given less often to control vision loss from macular edema, a swelling caused by a blocked retinal vein. Nearly 900 participants received either the higher dose or the standard lower dose,…

This study tested the safety of a longer-lasting clotting factor injection called BAY94-9027 (Jivi) in children aged 7 to under 12 with severe hemophilia A. The treatment is designed to prevent and control bleeding episodes with fewer injections than standard therapies. Researche…

This study tested if a new drug, BAY 3018250, could dissolve dangerous leg blood clots (deep vein thrombosis) faster and more effectively than standard blood thinners. 258 adults with recent leg clots received either a single dose of the new drug or a placebo, alongside their usu…

This study followed 100 babies for several years after they received treatment for retinopathy of prematurity (ROP), an eye disease affecting premature infants. The main goal was to see how their vision, eye health, and overall development turned out long-term. Researchers checke…

This study tested a new scoring system to help doctors personalize treatment plans for people with hemophilia A when switching to a longer-lasting medication called Jivi. The score used factors like a person's bleeding history and activity level to assign one of three dosing sche…

This study collected real-world data to see how well the heart failure drug vericiguat works compared to standard treatments for Chinese patients. It followed 2,400 adults with a weakened heart who had recently been very sick. The main goal was to see if the drug could help patie…

This study tested how well the drug larotrectinib works against advanced solid tumors that have a specific genetic change called an NTRK fusion. It involved 215 adults with various cancer types who had already tried standard treatments. Larotrectinib is designed to block the abno…

This study tested whether people with chronic heart failure could safely start taking the medication vericiguat at a higher dose than usual. Researchers wanted to see if starting at 5 mg instead of 2.5 mg would help patients reach the full 10 mg treatment dose faster, potentially…

This large, completed Phase 3 trial tested whether adding a new drug called copanlisib to the standard treatment rituximab was better at delaying the return or worsening of cancer in patients with a slow-growing type of non-Hodgkin's lymphoma that had come back. It involved 458 a…

This study aimed to collect more safety information about an approved eye injection (aflibercept) for diabetic macular edema (DME) specifically in Indian patients. DME is a diabetes complication where fluid leaks into the retina, causing vision loss. Over 52 weeks, researchers mo…

This study tested whether a small tablet that sticks to the gum (Sitavig) helps cold sores heal faster than a dummy tablet. Adults who get frequent cold sores applied one tablet at home when they felt a sore starting. Researchers tracked how long it took sores to heal completely …

This study tested whether adding the medication finerenone to standard care could better protect kidney function in adults with both chronic kidney disease and type 1 diabetes. Researchers compared finerenone against a placebo (inactive pill) in 241 participants over 6 months of …

This large, completed study tested whether a daily pill called finerenone could slow the worsening of kidney disease in people who don't have diabetes. About 1,580 adults took either finerenone or a placebo pill for up to 4 years, while continuing their standard kidney care. Rese…

This study looked back at health records to see how well a heart failure medicine called vericiguat works for people in everyday German medical care. Researchers analyzed data from 500 adults with chronic heart failure who were newly prescribed the drug between 2021 and 2023. The…

This study followed over 1,400 men with advanced prostate cancer that had spread to their bones to monitor the long-term safety of the treatment Radium-223. Researchers tracked serious side effects, bone marrow health, and the risk of developing a second, unrelated cancer for up …

This early-stage study tested the safety of a new oral drug, BAY3283142, in people with high blood pressure and chronic kidney disease. The drug is designed to relax blood vessels. For 10 weeks, 75 participants took either the drug or a placebo pill, and researchers monitored the…

This study tested whether adding a new drug called darolutamide to standard hormone therapy helps men whose prostate cancer has spread. It involved 669 men and compared the combination to hormone therapy alone. The main goal was to see if the new combination could delay the cance…

This early-stage study tested a new oral drug called BAY2862789 in 45 people with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the body's own immune T-cells to fight cancer. Researchers primarily wanted to determine safe d…

This study monitored the safety and effectiveness of Kovaltry, a treatment for hemophilia A, in 230 patients during routine medical care in Japan. Researchers tracked side effects and how well the drug controlled bleeding episodes over two years. The goal was to gather real-world…

This first-in-human study tested the safety and effects of an oral drug called larotrectinib in adults with advanced solid tumors that have a specific genetic change (NTRK fusion). The trial involved 75 patients for whom other effective therapies did not exist. Researchers aimed …

This study allowed patients with pulmonary arterial hypertension (PAH) who had previously taken riociguat in Bayer clinical trials to continue receiving the medication long-term. The main goal was to monitor the drug's safety and side effects over an extended period. Only 18 pati…

This study compared two prostate cancer drugs, darolutamide and enzalutamide, to see if one causes fewer side effects like breast tenderness and tissue growth. Researchers tested 28 men whose prostate cancer had returned after initial treatment but hadn't spread significantly. Th…

This large, completed Phase 3 trial tested whether adding a radioactive drug called Radium-223 to standard care could help men with advanced prostate cancer that had spread to their bones and was no longer responding to hormone therapy. The main goal was to see if the treatment h…

This large, completed Phase 3 trial tested whether adding a new drug called darolutamide to standard hormone therapy and chemotherapy could help men with prostate cancer that has spread (metastasized). The study involved over 1,300 participants and aimed to see if this combinatio…

This study aimed to understand how much of a high-dose eye medication gets into the bloodstream when injected into both eyes. It involved 51 adults with diabetic macular edema or 'wet' age-related macular degeneration. Researchers measured the highest drug concentration in partic…

This study tested a new contrast agent called gadoquatrane for MRI scans of the body (excluding the brain and spine). Researchers wanted to see if this new agent, which uses a lower dose of the metal gadolinium, could produce images as good as or better than the standard contrast…

This study observed 1,500 women to understand how different vitamin supplement plans, taken before and during pregnancy, affect health outcomes for mother and baby. Researchers specifically tracked rates of common complications like anemia, preeclampsia, and low birth weight. The…

This large, international study tested whether a new oral blood thinner called asundexian could safely prevent another stroke in people who had just experienced a clot-based stroke or a high-risk mini-stroke (TIA). Over 12,000 participants took either asundexian or a placebo pill…

This study tested whether a new medication called elinzanetant could reduce hot flashes in women after menopause. Researchers compared elinzanetant against a placebo (dummy pill) in 396 postmenopausal women who experienced frequent moderate-to-severe hot flashes. Participants tra…

This study tested whether a new drug called elinzanetant could reduce hot flashes in postmenopausal women. Researchers compared it to a placebo in 628 women over 52 weeks, tracking how many hot flashes they had and how severe they were. The study also looked at whether the treatm…

This study tested whether a new medication called elinzanetant could improve sleep for women experiencing nighttime awakenings during menopause. Researchers compared elinzanetant against a placebo in 110 participants over 12 weeks, measuring sleep quality through overnight sleep …

This study tested whether a new drug called elinzanetant could safely reduce the number and severity of hot flashes in women after menopause. 400 postmenopausal women with frequent moderate-to-severe hot flashes took either elinzanetant or a placebo pill daily for up to 26 weeks.…

This study aimed to better understand sleep problems linked to menopause, such as waking up at night. Researchers observed 750 women in the U.S., aged 40-65, who reported these issues. They collected data from health records, questionnaires, and smartwatches to see how sleep was …

This study aimed to understand how the radioactive drug Radium-223 moves through and collects in bones, particularly in areas without tumors, in men with advanced prostate cancer that has spread to bones. Researchers enrolled 46 men with different amounts of bone spread and gave …

This study aims to understand how liver disease changes the way the body processes an experimental cancer drug called sevabertinib. Researchers compared about 20 people—half with moderate liver problems and half with healthy livers—after each took a single dose. By measuring drug…

This early-stage study tested how the body absorbs new pill versions of a drug called elinzanetant, which is being developed to treat hot flashes. The study involved 18 healthy female volunteers who took different pill forms over several weeks. Researchers measured the drug level…

This study looked back at medical records to learn which sequence of two approved drugs helps people with advanced colorectal cancer live longer after other treatments stop working. Researchers analyzed data from 818 patients who received the drugs regorafenib and TAS-102 in diff…

This study looked at existing medical records to understand if the order in which patients receive certain cancer treatments affects how long they live. Researchers examined data from 121 people in Europe with advanced colorectal cancer who had already tried multiple treatments. …

This study looked back at existing medical records to learn how a heart failure drug called vericiguat is used and what happens to patients in real-world Japanese clinics and hospitals. Researchers analyzed data from nearly 5,000 adults with chronic heart failure who started taki…

This study analyzed existing medical records from over 5,700 adults in Japan who had sepsis, a life-threatening blood infection. Researchers looked back at hospital data to understand how often sepsis leads to a dangerous blood clotting problem called DIC. The goal was to gather …

This study aimed to better understand how sepsis, a life-threatening infection, can lead to a dangerous blood clotting disorder called DIC. Researchers observed 150 adult sepsis patients in European intensive care units, collecting their standard medical data and blood samples to…